Chief Corporate Development Officer

April 25, 2023

Client Team Lead: Noah Parekh Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced today the hiring of four senior leaders with significant industry experience in both small and large pharmaceutical and biotech companies. The company plans to continue growing its team to power…

Read More

Chief Executive Officer placed at rapidly growing hemp biotech startup

June 27, 2022

The Strategy Medterra Pharmaceuticals in partnerships with Baylor, Texas Medical Center, and Houston VA was launched in 2020 with seed funding given from Medterra CBD, their commercial B2C business, to explore the therapeutic benefits of CBD and other natural compounds. Medterra Pharma needed a new CEO who knows relevant investors to sell the business and…

Read More

Strategic leadership identified to up level HR and Finance functions

April 25, 2022

Abeona Therapeutics is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. Their executive team is truly top notch after being revamped by the new CEO. His strategy was to hire strong leaders, who are well respected, with known reputations in the market. They had a need…

Read More

Innovative digital molecular analysis Med Tech appoints CPDO and VP Engineering duo

March 25, 2022

Atonarp’s optical, mass spectrometer, and advanced informatic/software offerings provide the ability to “digitize” diagnostic testing. By eliminating the need for existing reagents and chemistries their technology allows for a quick diagnostic for a variety of acute and chronic diseases, amongst other standard diagnostic panels. Led by seasoned investors and raised over $100MM to date, their…

Read More

LifeSci Search Makes Strategic CDO Placement at a Leader in the Medicinal Applications of Psychedelics

February 3, 2022

Beckley Psytech is a leading name in the medical applications of psychedelics, which are currently among the most intensely innovative pharmaceutical aids for psychiatry. Many neurological and psychiatric disorders are highly resistant to existing treatments while being widespread and frequently debilitating. The global cost of these illnesses, including substance abuse disorders and mood disorders, is…

Read More

Clinical Stage Biopharmaceutical Company Makes Strategic CFO Hire

February 3, 2022

Elpiscience is a clinical stage biopharmaceutical company focused on innovating and developing next-generation immunotherapy to benefit cancer patients worldwide. The company has a robust pipeline of globally innovative molecules, covering wide range of targets in immuno-oncology. It has four molecules in clinical trials (ES002, ES101, ES102, and ES104), and endeavors to clinically advance at least…

Read More

Late stage Biotech appoints CCO to lead first commercial launch

February 3, 2022

VBL Therapeutics is an Israel-based small cap, publicly traded (NASDAQ: VBLT) late clinical stage biotech focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications.  VBL has pioneered and is actively developing three novel platform technologies. The Company’s most advanced program is the anti-cancer gene-therapy…

Read More

IO Biotech | Capitalizing on Breakthrough Approval

December 21, 2021

IO Biotech is a leading name in cancer vaccines and immunotherapies. They approached LifeSci Search after several years of promising work with their proprietary dual-action platform, T-win, which allows their vaccines to activate T cells to target both cancer cells and the immunosuppressive tumor microenvironment. The company was in Phase I clinical trials for two…

Read More

Israeli Biotech | Increasing Stock with Strong Leadership

September 28, 2021

Entera Bio is an Israeli based, public, product focused biotech that specializes in the oral delivery of large molecules and biologics. They needed an east coast Chief Executive Officer who could work in tandem with the Israeli based Board of Directors as they worked to improve Entera’s stock price and continue to advance their clinical…

Read More

$200m Series B ADC Biotech in search of CMO pre IPO

September 28, 2021

Pyxis Oncology are an exciting Boston based biotech working on antibody drug conjugates and monoclonal antibodies to treat a range of cancer indications. They had raised around $200m from top tier investors including RA Capital, Pfizer Ventures, Longwood Fund, Ipsen Ventures, Perceptive Advisors, BVF Partners and more. Approaching their IPO date with no CMO on…

Read More